Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Compass Therapeutics and MiNK Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Compass Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 312.19%. MiNK Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 1,217.72%. Given MiNK Therapeutics’ higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Compass Therapeutics.
Institutional & Insider Ownership
Valuation and Earnings
This table compares Compass Therapeutics and MiNK Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compass Therapeutics | $850,000.00 | 301.08 | -$42.49 million | ($0.36) | -5.17 |
| MiNK Therapeutics | N/A | N/A | -$22.46 million | ($0.60) | -1.14 |
MiNK Therapeutics has lower revenue, but higher earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Compass Therapeutics and MiNK Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -30.89% | -29.36% |
| MiNK Therapeutics | N/A | N/A | -233.85% |
Risk and Volatility
Compass Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.
Summary
Compass Therapeutics beats MiNK Therapeutics on 7 of the 11 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
About MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
